Copyright
©The Author(s) 2021.
World J Methodol. May 20, 2021; 11(3): 61-74
Published online May 20, 2021. doi: 10.5662/wjm.v11.i3.61
Published online May 20, 2021. doi: 10.5662/wjm.v11.i3.61
Ref. | Study period | Number of patients | Proportion of pediatric patients (%) | Histology | Setting | Treatment | Dose (Gy) | Age (yr) | Tumor size | Prior irradiation | Follow-up duration | Tumor control or PFS (%) |
Barcia et al[73], 1994 | 1978-1991 | 16 | 50 | LGG | Primary or boost therapy | SRS by use of a cobalt source and stereoguide | Mean margin dose 21.7 Gy | Median age 20 yr (range: 4-68 yr) | - | 12 patients | Median 50 mo | Tumor control 81 |
Somaza et al[74], 1996 | 1990-1993 | 9 | 100 | Pilocytic astrocytoma | Adjuvant or salvage therapy | GKSRS | Median margin dose 15 Gy | Mean age 8.6 yr (range: 4-17 yr) | Mean tumor diameter 16 mm | 2 patients | Median 19 mo | Tumor control 100 |
Kida et al[75], 2000 | 2000 | 12 (total number of patients in the study is 51) | 100 | WHO Grade I low grade astrocytoma | As part of initial management or salvage therapy | GKSRS | Mean margin dose 12.5 Gy | Mean age 9.8 yr | Mean tumor diameter 25.4 mm | - | Mean 27.6 mo | Tumor control 91.7 |
Boëthius et al[76], 2002 | 1978-1997 | 19 | 84.2 | Pilocytic astrocytoma | Adjuvant therapy | GKSRS | Median margin dose 10 Gy | Mean age 10.6 yr (range: 2-60 yr) | Median 2.2 cc | 2 patients | Median radiological follow-up 4.7 yr | Tumor control 94.7 |
Hadjipanayis et al[77], 2003 | 1987-2000 | 49 | 59 | Pilocytic astrocytoma (37 patients) and WHO Grade II fibrillary astrocytoma (12 patients) | As part of initial management or salvage therapy | GKSRS | Median margin dose 15 Gy | Median age 14 yr (range: 3-52 yr) for patients with pilocytic astrocytoma and median age 25 yr (range: 5-57 yr) for patients with WHO Grade II fibrillary astrocytoma | Median 3.3 cc | 13 patients | Median 32 mo after SRS | Tumor control 67 |
Saran et al[78], 2002 | 1994-1999 | 14 | 100 | LGG | As part of initial management or salvage therapy | LINAC-based SRT | Total dose 50-55 Gy | Median age 8 yr (range: 5-16 yr) | Median 19.5 cc | 0 patient | Median 33 mo | PFS 87 at 3 yr |
Marcus et al[79], 2005 | 1992-1998 | 50 | - | WHO Grade I-II astrocytoma | Salvage therapy | LINAC-based SRT | Mean total dose 52.2 Gy | Median age 9 yr (range: 2-26 yr) | ≤ 5 cm in maximal dimension in all patients | 0 patient | Median 6.9 yr | PFS 82.5 at 5 yr, PFS 65 at 8 yr |
Wang et al[80], 2006 | 1993-2003 | 21 | - | LGG | Primary, boost, adjuvant or salvage therapy | GKSRS | Median margin dose 14.5 Gy | Median age 20 yr (range: 6-70 yr) | Median 2.4 cc | 7 patients | Median radiological follow-up 49 mo | Tumor control 67 |
Kano et al[81], 2009 | 1987-2006 | 50 | 100 | Pilocytic astrocytoma | As part of initial management or salvage therapy | GKSRS | Median margin dose 14.5 Gy | Median age 10.5 yr (range: 4.2-17.9 yr) | Median 2.1 cc | 5 patients | Median 55.5 mo | PFS 70.8 at 5 yr |
Henderson et al[82], 2009 | 1997-2004 | 12 | - | WHO Grade I LGG (10 patients), WHO Grade II LGG (2 patients) | As part of initial management or salvage therapy | GKSRS | Median margin dose 13 Gy | Median age 17.4 yr (range: 5.9-63 yr) | Median 4.4 cc | 4 patients | Median 48.2 mo | PFS 75 at 4 yr |
Weintraub et al[83], 2012 | 1989-2011 | 24 | 100 | LGG | As part of initial management or salvage therapy | GKSRS | Median margin dose 15 Gy | Median age 11 yr (range: 4-18 yr) | Mean 2.4 cc | 3 patients | Median imaging follow-up 74 mo | Tumor control 83 |
Hallemeier et al[84], 2012 | 1992-2005 | 18 | 33 | Pilocytic astrocytoma | As part of initial management or salvage therapy | GKSRS | Median margin dose 15 Gy | Median age 23 yr (range: 4-56 yr) | Median 9.1 cc | 10 patients | Median 8 yr | PFS 41 at 5 yr |
Lizarraga et al[85], 2012 | 1995-2010 | 12 | 41.7 | Pilocytic astrocytoma | Salvage therapy | LINAC-based SRS or SRT | Median dose 18.75 Gy for SRS and median dose 50.4 Gy for SRT | Median age 21 yr (range: 5-41 yr) | Median 6.5 cc for SRT and median 1.69 cc for SRS | 0 patient | Median 37.5 mo | PFS 73.3 at long term |
Simonova et al[86], 2016 | 1992-2002 | 25 | 100 | Pilocytic astrocytoma | As part of initial management or salvage therapy | GK-based SRS or SRT | Median margin dose 16 Gy for patients receiving single fraction, median dose 25 Gy for SRT | Median age 13 yr (range: 3-17 yr) | Median 2.7 cc | 2 patients | Median 15 yr | PFS 80 at 10 yr |
Trifiletti et al[87], 2017 | 1990-2015 | 28 | - | Pilocytic astrocytoma | As part of initial management or salvage therapy | GK-based SRS or SRT | Median margin dose 16 Gy | Median age 17.4 yr (range: 2-70.3 yr) | Median 1.84 cc | 4 patients | Median 5.4 yr | PFS 96 at 6 yr |
Gagliardi et al[88], 2017 | 2001-2014 | 39 | 23.8 | LGG | As part of initial management or salvage therapy | GKSRS | Median margin dose 15 Gy | Median age 31 yr (range: 9-72 yr) | Median 1.24 cc | 8 patients | Median 54.5 mo | PFS 52.8 at 5 yr |
- Citation: Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, Colak O, Ozcan F, Gundem E, Elcim Y, Dirican B, Beyzadeoglu M. Concise review of stereotactic irradiation for pediatric glial neoplasms: Current concepts and future directions. World J Methodol 2021; 11(3): 61-74
- URL: https://www.wjgnet.com/2222-0682/full/v11/i3/61.htm
- DOI: https://dx.doi.org/10.5662/wjm.v11.i3.61